Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment

References

• Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.
   PubMed Web of Science ®Google Scholar
• Heaphy MR Jr, Ackerman AB. The nature of solar keratosis: A critical review in historical perspective. J Am Acad Dermatol. 2000;43:138–150.
   PubMed Web of Science ®Google Scholar
• Rowert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, Actinic keratosis is an early in situ squamous cell carcinoma: A proposal for reclassification. Br J Dermatol. 2007;(156 suppl 3):8–12.
   PubMedGoogle Scholar
• Lawrence N. New and emerging treatments for photoaging. Dermatol Clin. 2000;18:99–112.
   PubMedGoogle Scholar
• Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42:25–28.
   PubMedGoogle Scholar
• Gupta AK, Davey V, McPhail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9:209–214.
   PubMed Web of Science ®Google Scholar
• Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982;7:631–632.
   PubMed Web of Science ®Google Scholar
• Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23:191–196.
   PubMed Web of Science ®Google Scholar
• Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW, Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995;32:95–98.
   PubMedGoogle Scholar
• Feldman SR, Fleischer AB Jr, Williford PM, Jorizzo JL. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol. 1999;40:43–47.
   PubMed Web of Science ®Google Scholar
• Williams HC. Actinic keratoses and Bowen's disease In: Williams HC, editor. Evidence based dermatology. 2nd ed. Malden, MA: Blackwell Publishing; 2008. p. 301–302.
   Google Scholar
• Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813–816.
   PubMedGoogle Scholar
• Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990–1000.
   PubMed Web of Science ®Google Scholar
• Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70:22–29.
   PubMed Web of Science ®Google Scholar
• Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: A double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5:133–139.
   PubMedGoogle Scholar
• Jorizzo J, Stewart D, Bucko A, Davis SA, Espy P, Hino P, Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335–339.
   PubMed Web of Science ®Google Scholar
• Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2:629–635.
   PubMedGoogle Scholar
• Dillaha CJ, Jansen GT, Honeycutt WM, Holt GA. Further studies with topical 5-fluorouracil. Arch Dermatol. 1965;92:410–417.
   PubMed Web of Science ®Google Scholar
• Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;(157 suppl 2):34–40.
   Google Scholar
• Shuttleworth D, Marks R. A comparison of the effects of intralesional interferon alpha-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease. J Dermatolog Treat. 1989;1:65–68.
   Google Scholar
• Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther. 2001;23:901–907.
   PubMed Web of Science ®Google Scholar
• Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001;23:908–920.
   PubMed Web of Science ®Google Scholar
• Weinstock MA, Bingham SF, Cole GW, Eilers D, Naylor MF, Kalivas J, Reliability of counting actinic keratoses before and after brief consensus discussion: The VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol. 2001;137:1055–1058.
   PubMedGoogle Scholar
• Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:176–181.
   PubMed Web of Science ®Google Scholar
• Breza T, Taylor R, Eaglstein WH. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol. 1976;112:1256–1258.
   PubMedGoogle Scholar
• Ostertag JU, Quaedvlieg PJ, van der Geer S, Nelemans P, Christianen ME, Neumann MH, A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med. 2006;38:731–739.
   PubMed Web of Science ®Google Scholar
• PDR guide to drug interactions, side effects, indications. Montvale, NJ: Thomson PDR; 2006. p. v.
   Google Scholar
• Habif TP. Clinical dermatology: A color guide to diagnosis and therapy. Philadelphia: Mosby; 2004.
   Google Scholar